Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
Recruiting
Phase 2
Interventional Study
Indolent B-Cell Non-Hodgkin Lymphoma
Recurrent Indolent B-Cell Non-Hodgkin Lymphoma
Refractory Indolent B-Cell Non-Hodgkin Lymphoma
Recurrent Indolent Non-Hodgkin Lymphoma
Refractory Indolent Non-Hodgkin Lymphoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 112 (estimated)
- Sponsor
- Mayo Clinic · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually deliv…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 18 years
* Histological confirmation of indolent B-cell lymphoma that can include any of the following:
* Follicular lymphoma (grade 1 or 2 or 3A)
* Marginal zone lymphoma (nodal or extranodal)
* Follicle center lymphoma
* Any stage disease
* Initial, refractory, …
Contacts